Novel diazabicyclononene derivatives

A compound of formula I

• wherein
• W is a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in meta or para position;
• V represents —O—CH2—CH(OCH3)—CH2—O:
• —O—CH2—CH(CH3)—CH2—O—1;
• —O—CH2—CH(CF3)—CH2—O—;
• —O—CH2—C(CH3)2—O—;
• —O—C(CH3)2—CH2—1O—;
• —O—CH2—CH(CH3)—O—;
• —O—CH(CH3)—CH2—O—;
• —O—CH2—C(CH2CH2)—O—;
• or —O—C(CH2CH2)—CH12—O—;
• U represents aryl;
• or heteroaryl;
• T represents —CONR1—;
• —(CH2)pOCO—;
• —(CH2)pN(R1)CO—;
• —(CH2)pN(R1)SO2—;
• or —COO—;
• Q represents lower alkylene;
• or lower alkenylene;
• M represents hydrogen;
• cycloalkyl;
• aryl;
• heterocyclyl;
• or heteroaryl;
• L represents —R3;
• —COR3;
• —COOR3;
• —CONR2R3;
• —SO2R3;
• —SO2NR2R3;
• or —COCH(Aryl)2;
• R1 represents hydrogen;
• lower alkyl;
• lower alkenyl;
• lower alkinyl;
• cycloalkyl;
• aryl;
• or cycloalkyl-lower alkyl;
• R2 and R2′ independently represent hydrogen;
• lower alkyl;
• lower alkenyl;
• cycloalkyl;
• or cycloalkyl-lower alkyl;
• R3 represents hydrogen;
• lower alkyl;
• lower alkenyl;
• cycloalkyl;
• aryl;
• heteroaryl;
• heterocyclyl;
• cycloalkyl-lower alkyl;
• aryl-lower alkyl;
• heteroaryl-lower alkyl;
• heterocyclyl-lower alkyl;
• aryloxy-lower alkyl;
• or heteroaryloxy-lower alkyl, whereby these groups may be unsubstituted or mono- di- or trisubstituted with hydroxy, —OCOR2, —COOR2, lower alkoxy, cyano, —CONR2R2′, —CO-morpholin-4-yl, —CO-((4-loweralkyl)piperazin-1-yl), —NH(NH)NH2, —NR4R4′ or lower alkyl with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp3-hybridized;
• R4 and R4′ independently represent hydrogen;
• lower alkyl;
• cycloalkyl;
• cycloalkyl-lower alkyl;
• hydroxy-lower alkyl;
• —COOR2;
• or —CONH2;
• k is the integer 0 or 1;
• m and n represent the integer 0 or 1, with the proviso that in case m represents the integer 1, n is the integer 0, in case n represents the integer 1, m is the integer 0;
• and in case k represents the integer 0, n represents the integer 0;
• and
• p is the integer 1, 2, 3 or 4;
• or optically pure enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or the meso-form of the compound:
• or pharmaceutically acceptable salts, solvent complexes or morphological forms of the compound.